LENZ Therapeutics, Inc. (LENZ) Q4 2025 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Lenz Therapeutics, Inc..

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.031 -- 00:00:05.399 Ladies and gentlemen, and welcome to the Lent Therapeutics Year-End 2025 Financial 00:00:05.399 -- 00:00:10.446 Rituals Conference Call. At this time, all participants are in a distant 00:00:10.446 -- 00:00:12.148 old mood. 00:00:12.148 -- 00:00:17.255 While we prepare remarks for management, we will conduct a question and answer session, 00:00:17.255 -- 00:00:20.360 and instructions will follow at that time. 00:00:20.360 -- 00:00:23.584 As a reminder, the call is being recorded. 00:00:23.584 -- 00:00:28.491 At this time, I would like to turn the call over to Dan Chandler, State Financial Officer. 00:00:28.491 -- 00:00:30.872 Please go ahead. 00:00:32.228 -- 00:00:35.492 Thank you. Good morning, and thank you for joining us today. 00:00:35.492 -- 00:00:39.237 My name is Dan Chevalard, Chief Financial Officer of Lens Therapeutics. 00:00:39.237 -- 00:00:43.642 We are joined today by Abe Stummel-Pennick, our President and Chief Executive Officer, 00:00:43.642 -- 00:00:47.166 and Shawn Olson, our Chief Commercial Officer, as well as Dr. 00:00:47.166 -- 00:00:53.134 Mark Odrich, Chief Medical Officer, who will join us for the question and answer session. 00:00:53.134 -- 00:00:56.898 Before we begin, I would like to remind you that this call will contain forward-looking 00:00:56.898 -- 00:01:02.553 statements regarding Lens' future expectations, plans, prospects, 00:01:02.553 -- 00:01:07.739 corporate strategy, regulatory and commercial plans and expectations, cash runway 00:01:07.739 -- 00:01:10.363 projections, and performance. 00:01:10.363 -- 00:01:15.709 Actual results may differ materially from those indicated by these forward-looking statements 00:01:15.709 -- 00:01:20.275 as a result of various important factors and risks, includi...